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Copyright © 2015 Mar Quiñones et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Irisin is a cleaved and secreted fragment of fibronectin type III domain containing 5 (FNDC5) that is mainly released by skeletal
muscle and was proposed to mediate the beneficial effects of exercise on metabolism. In the present study we aim to investigate
the regulation of the circulating levels of irisin in obese animal models (diet-induced obese (DIO) rats and leptin-deficient (ob/ob)
mice), as well as the influence of nutritional status and leptin. Irisin levels were measured by Enzyme-Linked Immunosorbent
Assay (ELISA) and Radioimmunoassay (RIA). Serum irisin levels remained unaltered in DIO rats and ob/ob mice. Moreover, its
circulating levels were also unaffected by fasting, leptin deficiency, and exogenous leptin administration in rodents. In spite of these
negative results we find a negative correlation between irisin and insulin in DIO animals and a positive correlation between irisin
and glucose under short-term changes in nutritional status. Our findings indicate that serum irisin levels are not modulated by
different physiological settings associated to alterations in energy homeostasis. These results suggest that in rodents circulating
levels of irisin are not involved in the pathophysiology of obesity and could be unrelated to metabolic status; however, further
studies should clarify its precise role in states of glucose homeostasis imbalance.
1. Introduction
The combination of energy-dense diets and sedentary lifes-
tyles has accelerated the incidence of obesity and its comor-
bidities including dyslipidemia, diabetes mellitus, and car-
diovascular disease. Inflammatory processes play a crucial
role in the development of obesity. Adipose tissue release
cytokines such as IL-6 and IL-1𝛽 in obesity that targets
several tissues such as the heart, the pancreas, or the liver
[1]. Physical inactivity causes accumulation of visceral fat that
induces systemic low grade inflammation and in turn exercise
promotes a variety of metabolically beneficial effects in the
organism [2]. However, its mechanism of action remains
elusive and many efforts are focused to characterize new
molecular targets or mediators of these healthy benefits.
The skeletal muscle is considered nowadays as a complete
endocrine organ [3] and there are more than 1000 genes
activated by exercise [4]. One of these proposed mediators
is the peroxisome proliferator-activated receptor gamma
coactivator 1 alpha (PGC1-𝛼), a transcriptional coactivator
released by the muscle that induces mitochondrial biogenesis
and thus thermogenesis [5, 6] as well as modulating glucose,
lipid, and energy homeostasis [7, 8]. PGC1-𝛼 induces the
expression of the fibronectin type III domain containing
5 (FNDC5) gene that is cleaved and secretes a new hor-
mone from skeletal muscle named irisin [8]. FNDC5 was
simultaneously characterized in 2002 by two independent
groups [9, 10], but it was ten years later when irisin attracted
more interest because it was reported to act as a mediator
of the beneficial effect of exercise [8], increasing metabolic
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uncoupling and caloric expenditure and promoting browning
[8, 11, 12], resulting in an improvement of obesity and
glucose homeostasis. However, further studies performed in
animals and humans reported controversial results and the
physiological role of irisin is still under debate [2, 8, 13–18].
On the other hand, several studies assessed circulating
levels of irisin in humans and found controversial results
because some of them reported an increase of irisin under
conditions of obesity [19, 20] while others found a negative
association between irisin levels and obesity [21]. Further-
more recently no association was found between these two
parameters in humans [22]. Accordingly, circulating irisin
levels decreased after surgical [23] or dietary-induced [24]
weight loss. In rodents, gene expression results showed that
skeletal muscle FNDC5 mRNA levels were proportional to
circulating leptin levels [25] and the regulation of FNDC5
expression in DIO animals was different depending on the
fat depot [26]. However, there are no data on circulating
irisin levels in obese rodents and its regulation under certain
physiological conditions associated to body weight changes is
very scarce.The aim of this study was to assess the regulation
of serum irisin levels by nutritional status, leptin, and diet-
induced obesity in rodents.
2. Material and Methods
2.1. Animals. Male Sprague-Dawley rats (bred in the Ani-
malario Xeral of USC; Santiago de Compostela, Spain)
and ob/ob mice (Charles River, Barcelona, Spain) were
housed under conditions of controlled illumination (12 : 12-h
light/dark cycle), humidity, and temperature. Animals were
fed with a standard diet (Scientific Animal Food & Engi-
neering, proteins 16%, carbohydrates 60%, and fat 3%) and
tap water ad libitum unless otherwise indicated. The animals
were sacrificed in a room separate from other experimental
animals, and blood samples were centrifuged at 1500 g for
10min and the serumwas harvested and stored at−80∘Cuntil
an analysis could be performed. All experimental procedures
were reviewed and approved by the Ethics Committees of
the University of Santiago de Compostela in accordance
with the institutional guidelines and in strict compliance
with the European Union normative for the care and use of
experimental animals. The number of animals used in each
experimental setting is indicated in the corresponding figure’s
caption.
2.2. Experimental Setting 1: Effect of the Diet on Serum Irisin
Levels. After weaning, 6-week-oldmale Sprague-Dawley rats
were either fed a high-fat (HF) diet (60% by energy) or a
low-fat (LF) diet (10% by energy) (reference #: D12492 and
D12450B resp., Research Diets, NJ, US) for 10 weeks.
2.3. Experimental Setting 2: Effects of Food Deprivation on
Serum Irisin Levels. 10-week-old male rats were deprived of
food for 48 h, or refed for 24 h after fasting while the control
group was fed ad libitum [27, 28]. All animals had free access
to tap water.
2.4. Experimental Setting 3: Effects of Leptin on Serum Irisin
Levels. The effects of systemic leptin administration on
serum irisin levels were studied in leptin deficient mice
(ob/ob mice). Leptin-deficient animals were referred to wild
type (WT) control animals and were distributed in three
groups: (a) i.p. vehicle fed ad libitum, (b) i.p. vehicle after 36 h
fasting, and (c) i.p. leptin in fed ad libitummice. Animalswere
treated with recombinant leptin (L-4146, Sigma-Aldrich) at
a dose of 0.5mg/kg of body weight every 6 h for 3 days
(intraperitoneal injection) [29].
2.5. Measurement of Body Composition. Body composition
(fat and leanmass) was assessed usingNuclearMagnetic Res-
onance imaging system (Whole BodyCompositionAnalyzer;
EchoMRI, Houston, USA) as previously shown [30, 31].
2.6. Measurement of Biochemical and Hormonal Parameters.
Irisin and insulin levels were determined by ELISA using
reagents kits and methods provided by Phoenix Pharma-
ceuticals Inc. and by Millipore corporation, respectively.
These kits are suitable for human, rats, and mice and were
used in previous studies [20, 24, 32–34]. The quantitative
measurement of irisin in serum samples was performed using
a commercial ELISA kit directed against amino acids 33–142
of the FNDC5 protein (Irisin ELISA Kit EK-067-52; Phoenix
Pharmaceuticals Inc., CA) according to the manufacturer’s
instructions.The absorbance fromeach samplewasmeasured
in duplicate using a spectrophotometric microplate reader
at wavelength of 450 nm (Versamax Microplate Reader;
Associates of Cape Cod Incorporated, East Falmouth, MA).
The intra- and interassay coefficients of variation for the
kit were 4–6% and 8–10%, respectively. Irisin levels were
determined also by RIA using reagents kits and methods
provided by Phoenix Pharmaceuticals Inc. (Belmont, CA;
Cat. No. RK-067-16). For testing serum irisin levels, the
samples were obtained from trunk blood by decapitation and
were collected in tubes for serum separation (BD Vacutainer
SST II Advance). Results were expressed as ng per milliliter
of irisin in serum. Serum samples were tested in duplicate
within one assay, and the results were expressed in terms of
the rat irisin standard (ng/mL).
The absorbance from each sample with regard to insulin
levels was measured in duplicate using a spectrophotometric
microplate reader at wavelength of 450 nm and 590 nm. The
intra- and interassay coefficients of variation for the kit were
1–4% and 6–9%, respectively. Serum samples were tested in
duplicate within one assay, and the results were expressed in
terms of the rat insulin standard (ng/mL).
Glucose and total cholesterol was determined using
colorimetric assays (Spinreact, Girona, Spain) as previously
described [35].
2.7. Western Blot Analysis. Western blot was performed as
previously described [36, 37]. White adipose tissue (WAT)
and brown adipose tissue (BAT) were dissected and stored
at −80∘C until further processing.
WAT and BAT were homogenized in ice-cold lysis buffer
containing 50mmol/L Tris-HCl (pH 7.5), 1mmol/L EGTA,
1mmol/L EDTA, 1% Triton X-100, 1mmol/L sodium ortho-
vanadate, 50mmol/L sodium fluoride, 5mmol/L sodium
pyrophosphate, 0.27mol/L sucrose, 0.1% 2-mercaptoethanol,
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Table 1: Body composition and biochemical and hormonal characteristics from the models studied.
Group Insulin (ng/mL) Glucose (mg/dL) Total cholesterol (mg/dL) Fat mass (g) Lean mass (g)
Low fat 5.36 ± 1.08 18.51 ± 1.02 6.32 ± 0.40 56.53 ± 5.63 412.3 ± 4.0
High fat 9.07 ± 1.58∗ 25.86 ± 0.96∗∗∗ 7.14 ± 0.92 150.02 ± 23.04∗∗ 435.1 ± 5.5∗∗
Wild type mice 2.01 ± 0.42 2.41 ± 0.13 0.78 ± 0.07 — —
ob/ob mice FED 7.67 ± 1.63∗∗ 4.40 ± 0.72∗ 1.04 ± 0.03∗ — —
ob/ob mice FAST 4.35 ± 0.85 1.94 ± 0.34## 0.088 ± 0.04 — —
ob/ob mice FED + OB 1.32 ± 0.97### 3.24 ± 0.56 0.087 ± 0.02 — —
Rats FED 1.11 ± 0.22 20.16 ± 2.09 5.09 ± 0.83 26.21 ± 0.88 175.6 ± 3.4
Rats FAST 0.09 ± 0.007∗∗ 13.23 ± 0.71∗∗ 8.20 ± 0.32∗∗ 21.94 ± 0.71∗ 163.5 ± 1.9∗
Rats REFED 1.13 ± 0.19## 26.12 ± 0.78∗/### 6.14 ± 0.34# 23.52 ± 1.13 166.6 ± 3.4
Values are mean ± SEM of 7-8 animals per group. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001 versus controls. #𝑃 < 0.05; ##𝑃 < 0.01; ###𝑃 < 0.001 versus ob/ob
FED and versus FAST 48 h.
and complete protease and phosphatase inhibitor cocktail
(1 tablet/50mL; Roche Diagnostics, Mannheim, Germany).
Homogenates were centrifuged at 13,000 g for 10min at 4∘C,
supernatants were removed, and aliquots were stored in
−80∘C.
WAT and BAT lysates were subjected to SDS-PAGE gels.
Briefly, total protein lysates fromWAT and BAT (20𝜇g) were
subjected on 8% and 12% of SDS polyacrylamide gels and
electrotransferred on a polyvinylidene difluoride membrane.
Membranes were blocked for 1 h in TBS-Tween 20 (TBST:
50mmol/L Tris-HCl [pH 7.5], 0.15mol/L NaCl, and 0.1%
Tween 20) containing 3% of BSA and probed with for 16 h
at 4∘C in TBST, 3% BSA in the indicated antibodies: IL-6
(ab-6672), IL-1𝛽 (ab-9722) (Abcam, Cambridge, UK); PGC1𝛼
(sc-13067) (Santa Cruz Biotechnology, Santa Cruz, CA), 𝛼-
tubulin (T-5168), and 𝛽-actin (A-5316) (Sigma-Aldrich). For
protein detectionweusedhorseradish peroxidase-conjugated
secondary antibodies (Daku Denmark, Glostrup, Denmark)
and chemiluminescence (Pierce ECL Western Blotting Sub-
strate, Thermo scientific, USA). Then, the membranes were
exposed to X-ray film (Super RX, Fuji Medical X-Ray Film,
Fujifilm, Japan) and developed with developer and fixing
liquids (AGFA, Germany) under appropriate dark room
conditions.We used seven samples per group and the protein
levels were normalized to 𝛽-actin (WAT) and to 𝛼-tubulin
(BAT) for each sample.
2.8. Statistics. The results are shown as the mean ± standard
error of mean. Statistical analysis was performed using
Student’s 𝑡-test (when two groups were analysed) or one-
way ANOVA followed by a post hocmultiple comparison test
(Tukey Test) (when more than two groups were analysed). A
𝑃 value less than 0.05 was considered statistically significant;
Graph Prism software (San Diego, CA) was used for the data
analysis. For correlation studies statistical analyses were per-
formed using SPSS version 20.0 software statistical package
(SPSS, Chicago, IL).The relationships between variables were
analyzed by Pearson’s correlation (normally distributed data)
or Spearman’s rank correlation (nonnormally distributed
data) coefficients (𝑟). A 𝑃 value less than 0.05 was considered
statistically significant.
3. Results
As expected, the higher body weight in rats fed HF diet
(Figure 1(a)) was consistent with a significant increase in fat
and leanmass index compared to LF diet fed rats (Table 1) and
a significant increase in proteins levels of IL-1𝛽 in WAT but
not of IL-6 (Figure 2(a)). We do not have a clear explanation
for this fact but it could be due to the limited time of
exposition to the diet (10 weeks) or because a total positive
correlation between IL-6 and obesity is not always a strong
proof, due to the fact that a lack of IL-6 has been shown to
cause obesity and insulin resistance in rodents [38]. However,
the DIO rats eat less amount of food than the LF diet fed rats
because the HF diet is a hypercaloric food and these rats need
less quantity of food to be satiated compared to hypocaloric
LF diet fed animals (Figure 1(e)). Correspondingly, these
DIO rats are hyperglycemic and hyperinsulinemic (Table 1)
and display a trend of high cholesterol levels although this
trend is not significant (Table 1), as previously described
[22]. With regard to the monogenic model of obesity, the
ob/obmice exhibit a high body weight (Figure 1(b)) and food
intake (Figure 1(f)), and similar to the DIO rats, the ob/ob
mice display a significant increase in insulin, glucose, and
cholesterol levels with respect to WT controls (Table 1) and
high levels of inflammatory markers in WAT (Figure 2(b)).
Furthermore, we measure the levels of these biochemical and
hormonal parameters in the serum of rats submitted to short-
term changes in nutritional status. As expected, a 48 h fasting
induces a significant decrease in glucose and insulin serum
levels compared to ad libitum fed animals and a significant
increase in total cholesterol levels (Table 1) [39, 40].
Since circulating irisin levels are increased in human
obesity [19, 20], we assessed serum irisin levels in two animal
obese models: DIO rats as a model of polygenic obesity and
ob/ob mice as a model of monogenic obesity. In both rodent
obese models, serum irisin levels remained unaltered. Rats
fed a HF diet showed similar serum irisin levels as animals
fed a LF diet during 10 weeks (Figure 3(a)). Interestingly,
these results are consistent with a recent study in humans
[22]. Similarly, circulating irisin levels remained unaltered
between WT and obese mice lacking leptin (ob/ob mice)
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Figure 1: Body weight and food intake. (a) Body weight of rats fed with high fat (HF) and low fat (LF) diet. (b) Body weight in leptin deficient
mice (ob/ob) versus wild type (WT) mice fed ad libitum. (c) Body weight in ob/ob mice fed ad libitum, 36 hours fasted and after leptin
treatment in ob/ob mice fed ad libitum. (d) Body weight change in rats fed ad libitum, in 48 h of fasting and in rats submitted to a refeeding
for 24 h after 48 h of fasting. (e) Food intake of rats fed with high fat (HF) and low fat (LF) diet. (f) Food intake in leptin deficient mice (ob/ob)
versus wild type (WT) mice fed ad libitum. (g) Food intake in ob/ob mice fed ad libitum, 36 hours fasted and after leptin treatment in ob/ob
mice fed ad libitum. (h) Food intake in rats fed ad libitum, in 48 h of fasting and in rats submitted to a refeeding for 24 h after 48 h of fasting.
Values are mean ± standard error of the mean of 6–12 animals per group. Values are mean ± SEM. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001 versus
controls and #𝑃 < 0.05; ##𝑃 < 0.01; ###𝑃 < 0.001 versus FAST 48 h.
(Figure 3(b)). Of note, lack of differences in circulating irisin
in both models of obesity was found in spite of different
body weights (Figures 1(a) and 1(b)). As irisin levels were
unchanged in animal models of long-term obesity, we next
aimed to determine whether irisin might be regulated by
short-term changes in nutritional status. In order to test this
hypothesis, we measured irisin in animals fed ad libitum
and after food deprivation. Serum irisin levels remained
unaltered after 48 h of fasting or when rats were refed for
24 h (Figure 3(c)). As leptin is one of the main players in the
regulation of energy balance, we carried out a food depriva-
tion and leptin replacement in ob/obmice to corroborate our
previous data. Additionally, we measured the levels of PGC1-
𝛼, a proposed upstream regulator of irisin in BAT. We found
a very pronounced decreased in protein levels of PGC1-𝛼 in
ob/ob mice compared to WT mice (Figure 2(c)); however,
these levels were increased by leptin treatment (Figure 2(c))
as previously described [41, 42].
In agreement with our previous findings, we failed to
detect significant changes in circulating irisin levels in ob/ob
mice fasted for 36 h in comparison to ob/ob mice fed ad
libitum (Figure 3(d)), and the administration of exogenous
leptin to ob/ob mice did not cause any significant alteration
in serum irisin levels (Figure 3(d)). However, even though the
food deprivation and leptin caused a marked decrease in the
body weight (Figure 1(c)) and food intake (Figure 1(g)) and
changes in proteins levels of PGC1-𝛼 (Figure 2(c)) of leptin-
deficient mice.
Of note, this lack of differences in serum irisin levels in
all of these animal models was replicated in an independent
experiment by using a Radioimmunoassay (data not shown).
Finally, we have also performed correlations studies
between serum irisin versus body composition parameters
and biochemical and hormonal levels (Figures 4 and 5;
Table 2). We do not find any correlation between fat mass,
lean mass, or cholesterol levels and irisin in the different
models studied (Figures 4(a), 4(b), 4(c), and 4(d); Figures
5(a), 5(c), 5(d), 5(e), 5(f), 5(h), and 5(i); Table 2); however,
we detect a negative correlation between irisin and insulin in
the DIOmodel (Figure 5(b); Table 2) as previously described
in humans [21] and a positive correlation between glucose
and irisin under short-term changes in nutritional status
(Figure 5(g); Table 2).
4. Discussion
The discovery of irisin has created a great expectation due
to its proposed beneficial metabolic effects. However, the
knowledge about irisin regulation and secretion is still scant
and the results are controversial. In this sense, the levels
of circulating irisin in obesity have been reported to be
negatively associated to obese men [21], whereas others
indicated that irisin levels are high in obese individuals or are
positively correlated to body mass index [19, 20, 23, 43]. In
rodents, the results are equally ambiguous, as it was shown
that serum irisin levels are decreased in obese Otsuka Long-
Evans Tokushima Fatty (OLETF) rats in comparison to lean
rats [25], and in obese Zucker rats [26] but increased in DIO
rats [26]. In the current study, we have analyzed serum irisin
levels in two different obese animal models, DIO rats as a
model of polygenic obesity and in ob/ob mice as a model of
monogenic obesity. In both cases, our results were identical,























































































Figure 2: Measurements of protein levels in white and brown adipose tissue. WAT protein levels of IL-6 and IL-1𝛽 in DIO animals (a) and
in ob/ob mice (b). BAT protein levels of PGC1-𝛼 in ob/ob mice (c). 𝛽-actin for WAT and 𝛼-tubulin for BAT were used to normalize protein
levels. Values are mean ± SEM of 7-8 animals per group. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001 versus controls.
as we did not detect any significant difference between lean
and obese animals in concordance with a study in obese
humans [22]. Although all these results obtained in different
models of obese animals do not point in the same direction,
it is important to highlight that each model is associated
with different metabolic alterations that might affect irisin
levels. For instance, OLETF rats are diabetic whereas DIO
rats are insulin resistant but not diabetic. This is a key issue
since the role of irisin on glucose metabolism is still under
debate [21, 32, 44, 45]. Another crucial aspect that requires
attention is the methodology used for the measurement of
irisin. These methodological aspects are likely affecting the
results in DIO rats. In this sense, the study of Roca-Rivada
and colleagues assessed serum irisin levels by Western blot
[26] whereas we used a radioimmunoassay-basedmethod. In
spite of these discrepancies between different animal models
or methodologies, our present results suggest that circulating
irisin levels are not affected by obesity in rodents.
Since obese rodents represent models with long-term
metabolic alterations and compensatory mechanisms, we
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Figure 3: Serum irisin levels. (a) Serum irisin levels in rats fed with high fat (HF) and low fat (LF) diet for 10 weeks (b) Serum irisin levels in
leptin deficient mice (ob/ob) versus wild type (WT) mice fed ad libitum. (c) Serum irisin levels in animals fed ad libitum (FED), fasted for 48
hours (FAST 48 h) or refed for 24 hours (REFED 24 h) after 48 hours of fasting. (d) Serum irisin levels in ob/ob mice fed ad libitum, 36 hours
fasted, and in ob/ob mice fed ad libitum after leptin treatment. Values are mean ± SEM of the mean of 6–12 animals per group. A 𝑃 < 0.05
was considered significant.
Table 2: Correlations of irisin with body composition and biochemical and hormonal parameters from the models studied.
Group Irisin
Insulin (ng/mL) Glucose (mg/dL) Total cholesterol (mg/dL) Fat mass (g) Lean mass (g)
DIO 𝑟 = −0,668 𝑟 = −0,213 𝑟 = 0,288 𝑟 = −0,213 𝑟 = −0,213
𝑃 = 0.005∗∗ 𝑃 = 0.446 𝑃 = 0.299 𝑃 = 0.446 𝑃 = 0.446
ob/ob mice 𝑟 = 0,045 𝑟 = 0,06 𝑟 = −0,229 — —
𝑃 = 0.818 𝑃 = 0.974 𝑃 = 0.242 — —
FED-FAST-REFED 𝑟 = 0,250 𝑟 = 0,432 𝑟 = −0,123 𝑟 = −0,250 𝑟 = 0,040
𝑃 = 0.262 𝑃 = 0.045∗ 𝑃 = 0.587 𝑃 = 0.261 𝑃 = 0.859
Statistical significance is from Pearson (normally distributed data) and from Spearman (nonnormally distributed data) correlation test.
next evaluated if irisin levels might be affected in situations
of metabolic alterations at short term. The nutritional status
induces changes in a variety of endocrine axis and if irisin
has been proposed as a metabolic regulator, we hypothesized
that it should be regulated by fasting. However, we failed to
find any change in serum irisin levels by caloric restriction or
refeeding, indicating that its circulating levels are not affected
by nutritional status. Our findings are in agreement with a
previous study indicating that weight loss induced by caloric
restriction did not regulate circulating irisin levels in rats
[46]. On the other hand both fasting and caloric restrictions
are associated to a number of metabolic alterations, and
one of the most relevant is the decreased leptin levels.
Previous works have suggested a possible cross talk between
leptin and irisin because irisin levels are associated with
leptin in humans and rats [21, 25], and leptin increases

























































































Figure 4: Correlation of irisin levels with body composition parameters. Correlation of irisin with lean mass (a) and fat mass (b) in DIO
animals and with lean mass (c) and fat mass (d) in short-term changes of nutritional status.
mRNA expression of PGC1-𝛼 [41, 42], the proposed upstream
regulator of irisin [8]. Moreover recently it was shown that
leptin treatment slightly upregulates circulating irisin levels
in ob/ob mice [47]. Therefore, we decided to investigate in
depth the possible specific interaction between leptin and
irisin. In order to test this interaction, we measured irisin
levels in a model of hypoleptinemia performing a leptin
replacement in ob/obmice. Our data indicate that circulating
levels of irisin remained unaltered after leptin administration
in those mice in any experimental group. Therefore, these
results suggest that serum irisin levels are not modulated
by leptin on our experimental paradigms. Finally, we per-
form correlation studies of irisin with body composition,
biochemical and hormonal parameters. In concordance with
our previous results we do not find any correlation between
them in most of the parameters studied (Figures 4(a), 4(b),
4(c), and 4(d); Figures 5(a), 5(c), 5(d), 5(e), 5(f), 5(h), and
5(i); Table 2); however, in spite of these negative results we
detect a negative correlation between irisin and insulin in
DIO animals as previously described in obese subjects [21]













































































































































































































Figure 5: Correlation of irisin levels with biochemical and hormonal parameters. Correlation of irisin with glucose (a), insulin (b), and
cholesterol (c) in DIO animals; with glucose (d), insulin (e), and cholesterol (f) in ob/ob mice; with glucose (g), insulin (h), and cholesterol
(i) under short-term changes of nutritional status.
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and a positive correlation between irisin and glucose under
short-term changes in nutritional status (Figures 5(b) and
5(g); Table 2). These data indicate that irisin could play a role
in states that involve impairments of glucose homeostasis.
In summary, we conclude that serum irisin levels seems in
light of our present results not affected by obesity, nutritional
status, or leptin in rodents. However, it is important to note
that a limitation of the interpretation of the present results
is that the data are based on a direct determination of irisin
on serum samples without mechanism exploration or signal
transduction studies of irisin with metabolism in obesity
models. Further research on irisin will be necessary to clarify
its precise role in the regulation of energy balance and its
potential therapeutic use in obesity and its comorbidities.
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